Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-expressing dendritic cells

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2061-2073

  Pahne Zeppenfeld, Jennifer ^a   Schröer, Nadine ^a   Walch Rückheim, Barbara ^b   Oldak, Monika ^b   Gorter, Arko ^c   Hegde, Subramanya ^a   Smola, Sigrun ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CCR7; cervical cancer; human papillomavirus; interleukin 6; matrix metalloproteinase; tumor virology

Indexed keywords

CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6;

ADAPTIVE IMMUNITY; ARTICLE; BIOACCUMULATION; CANCER CELL; CARCINOGENESIS; CELL ACTIVATION; CELL FUNCTION; CELL HOMING; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CANCER;

CELL DIFFERENTIATION; CELL MOVEMENT; DENDRITIC CELLS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; MONOCYTES; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR7; UTERINE CERVICAL NEOPLASMS;

EID: 84896706222     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28549     Document Type: Article

References (50)

1. Bouvard V, Baan R, Straif K, et al.; W. H. O. International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
2. Fausch SC, Da Silva DM, Rudolf MP, et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169: 3242-9.
3. D'Costa ZJ, Jolly C, Androphy EJ, et al. Transcriptional repression of E-cadherin by human papillomavirus type 16 E6. PLoS One 2012; 7: e48954.
4. Matthews K, Leong CM, Baxter L, et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003; 77: 8378-85.
5. Giannini SL, Hubert P, Doyen J, et al. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97: 654-9.
6. Guess JC, McCance DJ,. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 2005; 79: 14852-62.
7. Sperling T, Ołdak M, Walch-Rückheim B, et al. Human papillomavirus type 8 interferes with a novel C/EBPbeta-mediated mechanism of keratinocyte CCL20 chemokine expression and langerhans cell migration. PLoS Pathog 2012; 8: e1002833.
8. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-97.
9. Hasan UA, Zannetti C, Parroche P, et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 2013; 210: 1369-87.
10. Ashrafi GH, Haghshenas MR, Marchetti B, et al. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005; 113: 276-83.
11. Campo MS, Graham SV, Cortese MS, et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 2010; 407: 137-42.
12. Stanley MA,. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012; 25: 215-22.
13. Schroer N, Pahne J, Walch B, et al. Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. Cancer Res 2011; 71: 87-97.
14. Heusinkveld M, de Vos, van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011; 187: 1157-65.
15. Dijkgraaf EM, Heusinkveld M, Tummers B, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 2013; 73: 2480-92.
16. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
17. Sheu BC, Lien HC, Ho HN, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63: 6537-42.
18. Hayati AR, Zulkarnaen M,. An immunohistochemical study of CD1a and CD83-positive infiltrating dendritic cell density in cervical neoplasia. Int J Gynecol Pathol 2007; 26: 83-8.
19. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33.
20. Saeki H, Moore AM, Brown MJ, et al. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999; 162: 2472-5.
21. Ratzinger G, Stoitzner P, Ebner S, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168: 4361-71.
22. Yen JH, Khayrullina T, Ganea D,. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008; 111: 260-70.
23. Hess S, Smola H, Sandaradura De Silva U, et al. Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. J Immunol 2000; 165: 1939-48.
24. Srivani R, Nagarajan B,. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 2003; 13: 331-9.
25. Bauknecht T, Randelzhofer B, Schmitt B, et al. Response to IL-6 of HPV-18 cervical carcinoma cell lines. Virology 1999; 258: 344-54.
26. Bertho N, Adamski H, Toujas L, et al. Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction. Blood 2005; 106: 1734-41.
27. Smola-Hess S, Schnitzler R, Hadaschik D, et al. CD40L induces matrix-metalloproteinase-9 but not tissue inhibitor of metalloproteinases-1 in cervical carcinoma cells: imbalance between NF-kappaB and STAT3 activation. Exp Cell Res 2001; 267: 205-15.
28. Hess S, Rensing-Ehl A, Schwabe R, et al. CD40 function in nonhematopoietic cells. Nuclear factor kappa B mobilization and induction of IL-6 production. J Immunol 1995; 155: 4588-95.
29. Oldak M, Tolzmann L, Wnorowski A, et al. Differential regulation of human papillomavirus type 8 by interferon regulatory factors 3 and 7. J Virol 2011; 85: 178-88.
30. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, et al. Monocyte-chemo- attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer 1999; 82: 6-11.
31. Altenburg A, Baldus SE, Smola H, et al. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol 1999; 162: 4140-7.
32. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003; 107: 407-15.
33. Wolenski M, Cramer SO, Ehrlich S, et al. Enhanced activation of CD83-positive T cells. Scand J Immunol 2003; 58: 306-11.
34. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760-9.
35. Hegde S, Pahne J, Smola-Hess S,. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J 2004; 18: 1439-41.
36. Hopken UE, Foss HD, Meyer D, et al. Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002; 99: 1109-16.
37. Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirus-related disease. Vaccine 2012; 30 (Suppl 5): F71-F82.
38. Mazibrada J, Ritta M, Mondini M, et al. Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol 2007; 108: 112-20.
39. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-56.
40. Trimble CL, Clark RA, Thoburn C, et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185: 7107-14.
41. Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010; 16: 98-105.
42. Naugler WE, Karin M,. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
43. Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48: 85-93.
44. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-96.
45. Puchalski T, Prabhakar U, Jiao Q, et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16: 1652-61.
46. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19: 3659-70.
47. Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65.
48. Sansone P, Bromberg J,. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30: 1005-14.
49. Kaisho T, Tanaka T,. Turning NF-kappaB and IRFs on and off in DC. Trends Immunol 2008; 29: 329-36.
50. St-Pierre Y, Couillard J, Van Themsche C,. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets 2004; 8: 473-89.